CA2294548A1 - Pyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors - Google Patents

Pyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors Download PDF

Info

Publication number
CA2294548A1
CA2294548A1 CA002294548A CA2294548A CA2294548A1 CA 2294548 A1 CA2294548 A1 CA 2294548A1 CA 002294548 A CA002294548 A CA 002294548A CA 2294548 A CA2294548 A CA 2294548A CA 2294548 A1 CA2294548 A1 CA 2294548A1
Authority
CA
Canada
Prior art keywords
alkyl
group
heterocyclic
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294548A
Other languages
English (en)
French (fr)
Inventor
Lawrence A. Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2294548A1 publication Critical patent/CA2294548A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002294548A 1997-08-22 1998-08-20 Pyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors Abandoned CA2294548A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91866197A 1997-08-22 1997-08-22
US08/918,661 1997-08-22
PCT/US1998/017618 WO1999010332A1 (en) 1997-08-22 1998-08-20 Prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
CA2294548A1 true CA2294548A1 (en) 1999-03-04

Family

ID=25440748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294548A Abandoned CA2294548A1 (en) 1997-08-22 1998-08-20 Pyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors

Country Status (10)

Country Link
EP (1) EP1005460B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002511887A (cg-RX-API-DMAC7.html)
AT (1) ATE319691T1 (cg-RX-API-DMAC7.html)
CA (1) CA2294548A1 (cg-RX-API-DMAC7.html)
CY (1) CY1105027T1 (cg-RX-API-DMAC7.html)
DE (1) DE69833774T2 (cg-RX-API-DMAC7.html)
DK (1) DK1005460T3 (cg-RX-API-DMAC7.html)
ES (1) ES2260846T3 (cg-RX-API-DMAC7.html)
PT (1) PT1005460E (cg-RX-API-DMAC7.html)
WO (1) WO1999010332A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
BR9813998A (pt) 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
PL198503B1 (pl) * 1998-10-27 2008-06-30 Abbott Lab Związki pirydazynonowe, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−3−オン誘導体及びこれを含有する医薬
CO5261556A1 (es) 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
JP2003523958A (ja) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−2の阻害剤、組成物ならびに使用法
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
BRPI0408359A (pt) 2003-03-18 2006-03-21 Kowa Co derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
JPWO2005012259A1 (ja) * 2003-07-30 2007-09-27 興和株式会社 オステオポンチン産生抑制方法
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
WO2018049027A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
DE69833774D1 (en) 2006-05-04
EP1005460B1 (en) 2006-03-08
ES2260846T3 (es) 2006-11-01
JP2002511887A (ja) 2002-04-16
DE69833774T2 (de) 2007-04-26
ATE319691T1 (de) 2006-03-15
EP1005460A1 (en) 2000-06-07
CY1105027T1 (el) 2010-03-03
DK1005460T3 (da) 2006-07-10
PT1005460E (pt) 2006-07-31
WO1999010332A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
EP1005460B1 (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors
EP1124804B1 (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors
CA2299300C (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
EP1206474B1 (en) Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
US7115591B2 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6300330B1 (en) Heterocycle derivatives which inhibit factor Xa
EP2331095A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PT98908A (pt) Processo de preparacao de compostos de pirimidina, piridina,piridazina, pirazina e triazina e de composicoes farmaceuticas que os contem
NZ231588A (en) Quinazoline-4-one derivatives, medicaments
EP0178189B1 (en) Pyridazinone derivatives, their preparation and use
EP1611121A1 (en) Pyridazinone derivatives as cdk2-inhibitors
CA2148477A1 (en) Further pyrimidine derivatives and their preparation
PT100158A (pt) Uso de antagonistas da angiotensina ii para a producao de um medicamento para otratamento de psoriase
JP3086692B2 (ja) 抗炎症剤としてのフエナメート1,3,4‐チアジアゾール類および1,3,4‐オキサジアゾール類
HU202106B (en) Process for producing pharmaceutical compositions containing pyrazolin derivatives
US6525053B1 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
WO2008156208A1 (ja) 5-フェニル-3-ピリダジノン誘導体
AU714597B2 (en) 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
CZ300847B6 (cs) Arylpyridazinony jako inhibitory biosyntézy prostaglandin endoperoxid H synthasy, jejich použití a farmaceutická kompozice s jejich obsahem
MXPA99011772A (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors
JPS60158150A (ja) 1,4‐ナフトキノン誘導体類
CA2578858A1 (en) Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued